Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 249-255, 2008. First published December 10, 2007; 10.1373/clinchem.2007.099366
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.099366v1
54/2/249    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ridker, P. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridker, P. M
(Clinical Chemistry. 2008;54:249-255.)
© 2008 American Association for Clinical Chemistry, Inc.


Special Reports

Rationale, Design, and Methodology of the Women’s Genome Health Study: A Genome-Wide Association Study of More Than 25 000 Initially Healthy American Women

Paul M Ridker1,2,a, Daniel I. Chasman1,2, Robert Y.L. Zee1,2, Alex Parker3, Lynda Rose1, Nancy R. Cook1,2, Julie E Buring1,2 for the Women’s Genome Health Study Working Group

1 Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston; 2 Donald W Reynolds Center for Cardiovascular Research, Harvard Medical School, Boston; 3 Amgen, Inc, Cambridge, MA.

aAddress correspondence to this author at: Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave East, Boston, MA 02215. Fax 617 734-1508; e-mail pridker{at}partners.org.

The primary aim of the Women’s Genome Health Study (WGHS) is to create a comprehensive, fully searchable genome-wide database of >360 000 single nucleotide polymorphisms among at least 25 000 initially healthy American women participating in the ongoing NIH-funded Women’s Health Study (WHS). These women have already been followed over a 12-year period for major incident health events including but not limited to myocardial infarction, stroke, cancer, diabetes, osteoporosis, venous-thromboembolism, cognitive decline, and common visual disorders such as age- related macular degeneration and cataracts. Investigations within the WGHS will seek to identify relevant patterns of genetic polymorphism that predict future disease states in otherwise healthy American women, and to evaluate patterns of genetic polymorphism that relate to multiple intermediate phenotypes including blood-based determinants of disease that were measured at baseline for each study participant. By linking genome-wide data to the existing epidemiologic databank of the parent WHS, which includes comprehensive dietary, behavioral, and traditional exposure data on each participant since cohort inception in 1992, the WGHS will also allow exploration of gene-environment and gene-gene interactions as they relate to incident disease states. Thus, with continued follow-up of the WHS, the WGHS provides a unique scientific resource—a full-cohort, prospective, genome-wide association study among initially healthy American women.




The following articles in journals at HighWire Press have cited this article:


Home page
JAMAHome page
T. A. Pearson and T. A. Manolio
How to Interpret a Genome-wide Association Study
JAMA, March 19, 2008; 299(11): 1335 - 1344.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.